Intra-amygdala infusion of zeta inhibitory peptide attenuates neuropathic pain but not inflammatory pain in adult rats

Juan Yao, Ling Zhang, Weiping Lei, Yaqin Huang, Honghai Zhang, Bo Lu, Yong-Xing Yao, Li Zhao, Jianliang SunAnnals 2019 · DOI

Abstract

Chronic pain is increasingly understood as a form of maladaptive memory maintained by specific molecular pathways in the brain. Protein kinase Mζ (PKMζ) is a key enzyme involved in long-term potentiation and memory storage. This study investigated whether inhibiting PKMζ in the basolateral amygdala (BLA) using zeta inhibitory peptide (ZIP) could alleviate neuropathic and inflammatory pain in rats. Results showed that intra-amygdala infusion of ZIP significantly reduced mechanical hyperalgesia in a chronic constriction injury (CCI) model of neuropathic pain when administered after the pain was established. However, ZIP had no effect on the development of neuropathic pain if given before injury, nor did it affect inflammatory pain induced by complete Freund’s adjuvant (CFA). These findings suggest that amygdalar PKMζ specifically maintains the "memory" of neuropathic pain, highlighting it as a potential therapeutic target.

Introduction

Chronic pain often persists long after the initial tissue damage has healed, a state characterized by central sensitization. Recent neuroscience research suggests that this persistence shares mechanisms with long-term memory. Protein kinase Mζ (PKMζ), a brain-specific PKC isoform, is essential for maintaining synaptic strength and memory. While its role in the spinal cord and cortex regarding pain is documented, its function in the amygdala—a hub for emotional pain processing—remains less clear. This study examines the effects of the PKMζ inhibitor, ZIP, on neuropathic and inflammatory pain models.

Methods

Adult male Sprague-Dawley rats were subjected to either Chronic Constriction Injury (CCI) of the sciatic nerve to model neuropathic pain or Complete Freund’s Adjuvant (CFA) injection to model inflammatory pain. Mechanical withdrawal thresholds (MWT) were measured to assess pain levels. ZIP, a scrambled control peptide (scr-ZIP), or saline was microinjected bilaterally into the BLA at various time points relative to the injury. Precise cannula placement was verified histologically.

Results

Neuropathic Pain (CCI Model)

The study found that ZIP did not prevent the induction of neuropathic pain when administered 30 minutes prior to CCI. However, when administered 3, 7, or 14 days after the injury, ZIP significantly increased the MWT, indicating a reduction in established pain. This effect was transient, with pain levels returning to baseline within 24 hours. Repeated administration of ZIP produced similar temporary relief.

Figure 1: Intra-amygdala infusion of ZIP significantly increases the mechanical withdrawal threshold 7 days after CCI, indicating a reduction in established neuropathic pain compared to control groups.

Inflammatory Pain (CFA Model)

In contrast to the results seen in the neuropathic pain model, intra-amygdala infusion of ZIP had no effect on mechanical hyperalgesia induced by CFA. MWT levels remained low and indistinguishable from control groups at all tested time points post-infusion, suggesting that the amygdala processes these two types of pain through distinct molecular pathways.

Figure 2: ZIP infusion into the amygdala shows no effect on mechanical withdrawal thresholds in the CFA-induced inflammatory pain model.

Conclusion

The findings demonstrate that PKMζ in the amygdala is specifically involved in the maintenance, but not the induction, of neuropathic pain. The lack of effect on inflammatory pain suggests that different chronic pain states utilize distinct central molecular mechanisms. Targeting PKMζ-mediated "pain memories" in the amygdala offers a novel avenue for treating persistent neuropathic pain, though the transient nature of the relief suggests the need for further exploration of the underlying neural circuits.

Summary updated

Abstract

Background: Protein kinase Mζ (PKMζ), a typical brain-specific PKC isoform, has been shown to be critical in the maintenance of long-term potentiation and memory storage. Zeta inhibitory peptide (ZIP), a peptide with selective inhibition of PKMζ, has been used in relieving experimental neuropathic pain and disrupting memory. The aim of this study was to investigate the effects of intra-amygdalar infusion of ZIP on neuropathic pain induced by chronic constriction injury (CCI), and inflammatory pain induced by complete Freund’s adjuvant (CFA) in adult rats. Methods: (I) ZIP was infused into the amygdala 30 minutes (min) before CCI was performed. Mechanical withdrawal threshold (MWT) was determined prior to the infusion of ZIP, and 30, 60, 90, 120, 150, 180 min after CCI (n=8 per group). (II) ZIP was infused into the amygdala 3, 7, 14 days after CCI (n=8 per group). MWT was measured 30 min before the infusion and 2, 12, 24 h after the infusion. (III) Three days after CCI, ZIP was infused into the amygdala repeatedly once a day for 2 days. MWT was measured before each infusion and 2 or 24 h after each infusion (n=8 per group). (IV) ZIP was infused into the amygdala 24 h after the establishment of inflammatory pain induced by complete Freund’s adjuvant (CFA). MWT was determined 30 min before the infusion and 30, 60, 90, 120 and 150 min after the infusion (n=8 per group). Results: As shown in figures, (I) amygdalar infusion of ZIP prior to the CCI produced no effect on CCI-induced hyperalgesia when compared to scr-ZIP or saline infusion [n=8, interaction effect, F (7.312, 76.776) =1.237, P>0.05; time as main factor, F (3.656, 76.776) =115.346, P<0.001; group as main factor, F (2, 21) =0.648, P>0.05]. (II) BLA infusion of ZIP significantly increased mechanical withdrawal threshold 7 days after CCI [n=8, interaction effect, F (5.476, 57.500) =15.279, P<0.001; time as main factor, F (2.738, 57.500) = 242.357, P<0.001; group as main factor, F (2,21) =4.786, P<0.05], just the same as 3 and 14 days after CCI (data not shown). (III) Bilateral injection of ZIP into the BLA significantly reduced mechanical hyperalgesia 2 h after the administration [n=8, paired t-test, t (0.05,7) =−5.561, P<0.05; n=8, paired t-test, t (0.05,7) =−4.745, P<0.05], and returned to baseline 24 h after the administration [n=8, paired t-test, t (0.05,7) =1.039, P>0.05; n=8, paired t-test, t (0.05,7) =−1.173, P>0.05]. (IV) ZIP produced no effect on mechanical withdrawal thresholds at all time points examined after the infusion, compared with scr-ZIP or saline control groups (n=8, interaction effect, F (6.135, 126) =1.724, P>0.05; group as main factor, F (2,21) =0.608, P>0.05). Conclusions: Intra-amygdala infusion of ZIP attenuates mechanical hyperalgesia induced by CCI but has no effect on inflammatory pain induced by CFA in rats, suggesting that amygdala PKMζ may be a therapeutic target in the treatment of neuropathic pain.
BibTeX
@article{yao2019intra,
  author = {Juan Yao and Ling Zhang and Weiping Lei and Yaqin Huang and Honghai Zhang and Bo Lu and Yong-Xing Yao and Li Zhao and Jianliang Sun},
  title = {{Intra-amygdala infusion of zeta inhibitory peptide attenuates neuropathic pain but not inflammatory pain in adult rats}},
  journal = {Annals},
  year = {2019},
  doi = {10.21037/apm.2019.11.21},
}
Figure